News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
345,770 Results
Type
Article (21090)
Company Profile (141)
Press Release (324525)
Multimedia
Podcasts (112)
Webinars (17)
Section
Business (105928)
Career Advice (891)
Deals (18672)
Drug Delivery (110)
Drug Development (51064)
Employer Resources (80)
FDA (7855)
Job Trends (7826)
News (186983)
Policy (17481)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (739)
Accelerated approval (19)
Adcomms (23)
Allergies (82)
Alliances (27977)
ALS (90)
Alzheimer's disease (790)
Antibody-drug conjugate (ADC) (207)
Approvals (8033)
Artificial intelligence (282)
Autoimmune disease (82)
Automation (15)
Bankruptcy (178)
Best Places to Work (5555)
BIOSECURE Act (14)
Biosimilars (170)
Biotechnology (60)
Bladder cancer (74)
Brain cancer (34)
Breast cancer (264)
Cancer (2310)
Cardiovascular disease (239)
Career advice (740)
Career pathing (24)
CAR-T (111)
CDC (14)
Cell therapy (288)
Cervical cancer (11)
Clinical research (44821)
Collaboration (1010)
Company closure (1)
Compensation (372)
Complete response letters (52)
COVID-19 (1155)
CRISPR (49)
C-suite (533)
Cystic fibrosis (88)
Data (3296)
Decentralized trials (2)
Denatured (27)
Depression (83)
Diabetes (249)
Diagnostics (1890)
Digital health (15)
Diversity (9)
Diversity, equity & inclusion (22)
Drug discovery (170)
Drug pricing (200)
Drug shortages (33)
Duchenne muscular dystrophy (138)
Earnings (40904)
Editorial (46)
Employer branding (10)
Employer resources (78)
Events (50927)
Executive appointments (619)
FDA (9433)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (3)
Frontotemporal dementia (5)
Funding (651)
Gene editing (90)
Generative AI (31)
Gene therapy (269)
GLP-1 (824)
Government (2019)
Grass and pollen (4)
Guidances (205)
Healthcare (5920)
HIV (28)
Huntington's disease (24)
IgA nephropathy (60)
Immunology and inflammation (168)
Immuno-oncology (35)
Indications (68)
Infectious disease (1288)
Inflammatory bowel disease (120)
Inflation Reduction Act (12)
Influenza (46)
Intellectual property (136)
Interviews (118)
IPO (7431)
IRA (53)
Job creations (2442)
Job search strategy (653)
JPM (52)
Kidney cancer (10)
Labor market (61)
Layoffs (343)
Leadership (27)
Legal (4157)
Liver cancer (37)
Longevity (8)
Lung cancer (333)
Lymphoma (208)
Machine learning (21)
Management (31)
Manufacturing (524)
MASH (104)
Medical device (2003)
Medtech (2011)
Mergers & acquisitions (11769)
Metabolic disorders (885)
Multiple sclerosis (103)
NASH (20)
Neurodegenerative disease (161)
Neuropsychiatric disorders (71)
Neuroscience (1519)
Neurotech (1)
NextGen: Class of 2026 (2363)
Non-profit (915)
Now hiring (45)
Obesity (517)
Opinion (232)
Ovarian cancer (66)
Pain (147)
Pancreatic cancer (95)
Parkinson's disease (155)
Partnered (18)
Patents (279)
Patient recruitment (243)
Peanut (19)
People (34479)
Pharmaceutical (76)
Pharmacy benefit managers (33)
Phase 1 (14119)
Phase 2 (18903)
Phase 3 (15203)
Pipeline (2896)
Policy (235)
Postmarket research (1619)
Preclinical (4935)
Press Release (29)
Prostate cancer (131)
Psychedelics (27)
Radiopharmaceuticals (181)
Rare diseases (527)
Real estate (3204)
Recruiting (33)
Regulatory (13768)
Reports (25)
Research institute (835)
Resumes & cover letters (140)
Rett syndrome (6)
RNA editing (12)
RSV (43)
Schizophrenia (118)
Series A (119)
Series B (83)
Service/supplier (7)
Sickle cell disease (65)
Special edition (21)
Spinal muscular atrophy (119)
Sponsored (18)
Startups (2040)
State (2)
Stomach cancer (12)
Supply chain (76)
Tariffs (94)
The Weekly (83)
Vaccines (403)
Venture capital (68)
Weight loss (378)
Women's health (40)
Worklife (9)
Date
Today (36)
Last 7 days (263)
Last 30 days (1039)
Last 365 days (15277)
2026 (1500)
2025 (15485)
2024 (17669)
2023 (19639)
2022 (25871)
2021 (26648)
2020 (24873)
2019 (20060)
2018 (15587)
2017 (17254)
2016 (16204)
2015 (18803)
2014 (14789)
2013 (12555)
2012 (13483)
2011 (13817)
2010 (12738)
Location
Africa (414)
Alabama (41)
Alaska (1)
Arizona (92)
Arkansas (8)
Asia (25939)
Australia (3333)
California (4791)
Canada (1820)
China (748)
Colorado (196)
Connecticut (195)
Delaware (180)
Europe (53486)
Florida (833)
Georgia (97)
Hawaii (2)
Idaho (18)
Illinois (441)
India (51)
Indiana (294)
Iowa (5)
Japan (322)
Kansas (83)
Kentucky (29)
Louisiana (7)
Maine (4)
Maryland (596)
Massachusetts (3855)
Michigan (68)
Minnesota (241)
Mississippi (3)
Missouri (42)
Montana (12)
Nebraska (14)
Nevada (35)
New Hampshire (10)
New Jersey (1854)
New Mexico (21)
New York (1312)
North Carolina (793)
North Dakota (2)
Northern California (2242)
Ohio (129)
Oklahoma (8)
Oregon (23)
Pennsylvania (1059)
Puerto Rico (19)
Rhode Island (27)
South America (616)
South Carolina (11)
Southern California (2030)
Tennessee (64)
Texas (653)
United States (18155)
Utah (94)
Virginia (177)
Washington D.C. (60)
Washington State (375)
West Virginia (1)
Wisconsin (49)
Wyoming (1)
345,770 Results for "meiji seika pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery
December 19, 2025
·
2 min read
Press Releases
Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing
December 3, 2025
·
2 min read
Press Releases
Meiji Seika Pharma: Announcement of the Establishment of Local Subsidiary “Taiwan Meiji Pharma Co., Ltd.” in Taiwan
December 25, 2024
·
1 min read
Press Releases
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
November 14, 2024
·
3 min read
Press Releases
Meiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy
January 10, 2025
·
1 min read
Press Releases
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
January 31, 2025
·
2 min read
Drug Development
Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023
Meiji Seika Pharma Co., Ltd. announced that positive findings from the phase II clinical trial of ME3183, a novel highly-potent selective phosphodiesterase-4 inhibitor, in patients with plaque psoriasis conducted in the United States and Canada were presented on 12 October at the European Association of Dermatology and Venereology Congress 2023 held in Berlin.
October 13, 2023
·
2 min read
Drug Development
Meiji Seika Pharma Announces Positive Results in Phase II Study of ME3183, a Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis in the United States and Canada
Meiji Seika Pharma Co., Ltd. announced that ME3183, a novel highly-potent selective phosphodiesterase-4 inhibitor, met the primary endpoint based on “PASI-75”, defined as the proportion of subjects achieving 75% improvement in Psoriasis Area Severity Index, in phase II clinical trial in patients with moderate-to-severe plaque psoriasis conducted in the United States and Canada.
August 9, 2023
·
1 min read
Press Releases
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
September 13, 2024
·
7 min read
Press Releases
As mental health patients turn to AI chatbots, how can pharma lead the way?
A new report by Bryter released today reveals where pharma can lead as patients turn to (and question) AI tools for mental health.
February 5, 2026
·
1 min read
1 of 34,577
Next
